An interventional study of Control and FreeDom in Oxygen Deficiency and COPD Exacerbation, sponsored by Laval University. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Laval University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Hypoxia with a site in Canada — 7 open to participants now, 12 under way, 1 of them phase 3. Hypoxia · Canada.
Among the 50 studies in Hypoxia with a site in Canada, this one is the 7th largest by planned enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2018, is one of 30 with no phase, reaches primary completion later than 11 of the 11 other live ones, and was the 30th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →7 of the 50 studies in Hypoxia with a site in Canada are open now. Recruiting first, the newest first:
University of Ottawa · Sites in Canada
Ages 18–70 · Healthy volunteers
Laval University · Sites in Canada, Guadeloupe, Tunisia
Ages 0–100
University of Alberta · Sites in Canada
Ages 18–65 · Healthy volunteers
Laval University · Sites in Canada
Ages 18+
Erasmus Medical Center · Sites in Canada, Belgium, Netherlands
Ages 23 wk–29 wk
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 2 · Phase 3 1 · Phase 4 3
First in 1999; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 25 across the 41 interventional studies, 133 across the 9 observational. Of the 34 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 50 have an industry lead sponsor. The 10 most frequent:
Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Laval University has 9 studies filed under Hypoxia — fewer than ten, so there is no comparison to draw.
6 of the studies in Hypoxia with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06661525University of British ColumbiaMonitoring Free Tissue Transfer Hemodynamics Using NIRS | 2026-12-29 |
| NCT07664462University of OttawaWorking in the Heat at Simulated Altitude: Effects of Normobaric Hypoxia on Physiological Strain | 2026-12-31 |
| NCT05467215University of AlbertaCan Brief Exposure to Hyperoxia Improve Function After Chronic Spinal Cord Injury? | 2026-12-31 |
| NCT04395469University Health Network, TorontoFAZA PET/MRI Pancreas | 2027-03 |
| NCT06102499Laval UniversityComparison of Pulse Oximetry (SpO2) With Different Oximeters and Arterial Saturation (SaO2): Oxygap2 Study | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Hypoxia with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the study is to assess the "FreeDom" innovative strategy (FreeO2 at Domicile) to reduce hospitalization duration in patients with COPD exacerbation. This strategy associates early hospital discharge, automated O2 flow weaning with FreeO2 system, telemedicine and tele-rehabilitation.
The main hypothesis of this study is that the FreeDom strategy will reduce the number of hospitalization day by 50 percent at day 30.
The main objective of the study is to assess the "FreeDom" innovative strategy (FreeO2 at Domicile) to reduce hospitalization duration in patients with COPD exacerbation. This strategy will enable an early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation.
The main hypothesis of this study is that a strategy for an early return home with a home hospitalization managed by telemedicine will reduce the length of hospitalization by 50 percent from 30 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients hospitalized for exacerbation for less than 48 hours will be considered.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention is an hospitalization with usual care. The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
Other: Control
FreeDom strategy (early discharge, automated weaning at home, telemedicine, telereadaptation): -initial conventional hospitalization before discharge home, O2 flow rate automatically titrated by FreeO2 (based on a SpO2 target). The hospital discharge will be possible if the definite criteria are met. After hospital discharge, patient will have home hospitalisation. Automated oxygen flow titration, patient education will be conducted for using the telemedicine system, for questionnaires and for the tele-rehabilitation program will be initiated for home hospitalization,
Device: FreeDom
The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
Also known as: Usual oxygen administration and usual hospitalization
Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
Also known as: Early Hospital discharge with home hospitalisation
The number of hospital days during COPD exacerbation at day 30.
The objective of the study is to reduced the hospitalisation days by 50 % at day 30 during COPD exacerbation
Time frame: 30 days
Rate of Emergency consultation and hospital readmission
Rate of Emergency consultation and hospital readmission
Time frame: 1 and 3 months
Health Related Quality of Life
Survey of health related quality of life
Time frame: 1 and 3 months
Cost of care at 3 months
Economic evaluation about these 2 different strategy of COPD exacerbation management using micro-costing approach and including the cost of the FreeO2 technology
Time frame: 3 months
Oxygenation data (% of time in the SpO2 target, % of time with hypoxemia, % of time with hyperoxia)
The continuous measurement of SpO2 and O2 flow rate with the FreeO2 device (only in the FreeDom strategy) will allow the calculation of the % of time within the SpO2 target (recorded in the FreeO2) ± 2%, with hypoxemia (% of time with SpO2 \< 85%) and with hyperoxia (% of time above SpO2 target +5%)
Time frame: From inclusion to hospital discharge and from hospital discharge to the end of oxygen therapy (around one week after discharge)
Number of consultations
Number of consultation : phone call, video consultation, rehabilitation, home visit
Time frame: 3 months
Started May 2018 (actual). Primary completion is estimated for Jun 2030, 145 months after the start.
Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 145 months is above that.
Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jun 2025 → Jun 2030 and completion Dec 2025 → Dec 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.